Compositions for inhalation
AssigneeAstraZeneca AB
InventorsKjell Göran Erik Bäckström, Carl Magnus Olof Dahlbäck, Peter Edman, Ann Charlotte Birgit Johansson
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition including a mixture of active compounds (A) a pharmaceutically active polypeptide, and (B) an enhancer compound which enhances the systemic absorption of the polypeptide in the lower respiratory tract of a patient, the mixture being in the form of a dry powder for inhalation in which at least 50% of the total mass of the active compounds consists of primary particles having a diameter less than or equal to about 10 microns, the primary particles optionally being formed into agglomerates.
Claims43
A composition consisting essentially of (A) a polypeptide, (B) one or more substances which enhance the absorption of said polypeptide in the lower respiratory tract, and (C) optionally one or more non-hygroscopic additives, said composition being in the form of a dry powder suitable for inhalation from a dry powder inhaler, wherein at least 50% of the total mass of (A) and (B) consists of primary particles having a diameter of up to about 10 microns, provided that each of said one or more substances is selected from the group consisting of a C8-C16 fatty acid, a salt of said fatty acid, a salt of glycyrrhizine acid, an acyl carnitine, and an alkyl saccharide.
A composition consisting essentially of (A) a polypeptide, (B) one or more phospholipids that enhance the absorption of said polypeptide in the lower respiratory tract, and (C) optionally one or more non-hygroscopic additives, said composition being in the form of a dry powder suitable for inhalation from a dry powder inhaler, wherein at least 50% of the total mass of (A) and (B) consists of primary particles having a diameter of up to about 10 microns.
Dependencies are inferred from the claim text.